p63 是否可以作为诊断骨巨细胞瘤的生物标志物？系统评价和荟萃分析。
Can p63 serve as a biomarker for diagnosing giant cell tumor of bone? A systematic review and meta-analysis.
机构信息
MD. Doctoral Student, Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong Kong, China.
PhD. Research Associate Professor, Institute for Tissue Engineering and Regenerative Medicine, The Chinese University of Hong Kong; and Research Associate Professor, School of Biomedical Science, The Chinese University of Hong Kong, Hong Kong, China.
出版信息
Sao Paulo Med J. 2020 Sep-Oct;138(5):393-399. doi: 10.1590/1516-3180.2020.0021.R3.24062020.
BACKGROUND
Tumor protein p63 (p63) has been reported to be highly expressed in giant cell tumor of bone (GCTB). Whether p63 can be treated as a diagnostic marker for GCTB remains unclear.
OBJECTIVE
We conducted a meta-analysis to evaluate the applicability of p63 in diagnosing GCTB.
DESIGN AND SETTING
Systematic review and meta-analysis carried out in a public hospital, Hong Kong, China.
METHODS
We searched PubMed, EMBASE and the Cochrane Library from inception to April 30, 2019. Literature in English or Chinese about the differential diagnosis of GCTB using p63 were included. -Animal experiments, reviews, correspondence, case reports, expert opinions and editorials were excluded. Studies were also excluded if they did not provide sufficient information to construct a 2 × 2 contingency table. We calculated individual and pooled sensitivities and specificities. We used I² as an indicator of heterogeneity.
RESULTS
Out of 88 records identified, 8 articles on 788 GCTB patients fulfilled the inclusion criteria and were included in the present analysis. Bivariate analyses yielded a pooled mean sensitivity of 0.87 (95% confidence interval, CI, 0.72-0.95) and specificity of 0.71 (95% CI, 0.56-0.82) for using p63 as a biomarker in diagnosing GCTB. The area under the receiver operating characteristic curve was 0.86 (95% CI, 0.82-0.88).
CONCLUSION
p63 is a helpful indicator in diagnosing GCTB due to its high sensitivity and specificity. -Nonetheless, the results need to be carefully interpreted based on other diagnostic methods such as imaging.
SYSTEMATIC REVIEW REGISTRATION
164115 (PROSPERO registration number).
背景
肿瘤蛋白 p63（p63）在骨巨细胞瘤（GCTB）中表达较高。p63 是否可作为 GCTB 的诊断标志物尚不清楚。
目的
我们进行了一项荟萃分析，以评估 p63 在诊断 GCTB 中的适用性。
设计和设置
在中国香港公立医院进行的系统评价和荟萃分析。
方法
我们检索了 PubMed、EMBASE 和 Cochrane 图书馆，检索时间截至 2019 年 4 月 30 日。纳入使用 p63 对 GCTB 进行鉴别诊断的英文或中文文献。排除动物实验、综述、信函、病例报告、专家意见和社论。如果研究未提供足够的信息来构建 2×2 四格表，则将其排除。我们计算了个体和汇总的敏感性和特异性。我们使用 I²作为异质性的指标。
结果
在 88 条记录中，有 8 篇关于 788 例 GCTB 患者的文章符合纳入标准，并纳入了本分析。二项分析得出，使用 p63 作为诊断 GCTB 的生物标志物，汇总的平均敏感性为 0.87（95%置信区间，0.72-0.95），特异性为 0.71（95%置信区间，0.56-0.82）。受试者工作特征曲线下面积为 0.86（95%置信区间，0.82-0.88）。
结论
由于 p63 具有较高的敏感性和特异性，因此它是诊断 GCTB 的有用指标。然而，结果需要根据其他诊断方法（如影像学）进行仔细解释。
系统评价注册
164115（PROSPERO 注册号）。
Zotero 插件